The Column Group
Venture capitalActively deployingSan Francisco · Pre-Seed–Late Stage · 26 people tracked
Also known as Column Capital Advisors, Llc · THE COLUMN GROUP MANAGEMENT LP
Investment thesis
TCG pursues a science-driven approach to biotech venture capital, emphasizing company formation while retaining the capital resources to support ventures over the long term across both private and public markets. Its ecosystem comprises multiple complementary funds—TCG Platform funds, TCG Opportunity funds, TCG Labs-Soleil, and TCG Crossover (TCGX)—each with a distinct strategy for deploying capital into technology platforms, single assets, and later-stage programs. The funds collaborate to advance biology, chemistry, and technology innovations from inception through exit, aiming to turn scientific discoveries into successful biotech companies.
Source: firm website, verified Aug 3, 2026.
Team · 26 people
from public directories
What they invest in
from 27 of 60 portfolio companiesBiotech ×25Medical Devices ×8Healthtech ×7AI & Machine Learning ×3Deep Tech ×3Digital Health ×2Cybersecurity ×1Developer Tools ×1
HQs:United States×26
Investments · 60 tracked
founders shown can be your intro pathSan Francisco, US
David Goeddel(Director)Mark Goldsmith(Director)Arthur T. Sands(Executive Officer, Director)Timothy Kutzkey(Executive Officer, Director)
Board seatDavid Goeddel· per SEC Form D · $17M raise · filed Sep 2015
Johnson & Johnson is a diversified healthcare company operating across 260 subsidiary companies with approximately 138,000 employees globally.
BiotechHealthtechMedical DevicesNew Brunswick, US
ORIC Pharmaceuticals is a clinical-stage oncology company founded in 2014 to develop cancer therapies that address treatment resistance, with the aim of extending the effectiveness of existing therapies.
BiotechHealthtechSouth San Francisco, US
Steve L. Hoerter(Director)Lori Kunkel(Director)Jacob M. Chacko(Executive Officer, Director)Richard Heyman(Chairman, Founder, Scientific Advisory Board)Dominic Piscitelli(Chief Financial Officer)Angie You(Director)
Remix Therapeutics develops RNA reprogramming technology to treat various diseases and disorders.
AI & Machine LearningBiotechWatertown, US
Peter Smith, PhD(Co-Founder, President and Chief Executive Officer)Peter Smith(Co-Founder, President and Chief Executive Officer)Robert Gagnon(Executive Officer)Matthew Patterson(Director)Kevin Bitterman(Director)Jeff Goater(Director)
Board seatJeff Goater· per SEC Form D
A2 Biotherapeutics develops precision CAR T-cell therapies for people with cancer and other diseases using its Tmod cell engineering platform for autologous and allogeneic applications.
BiotechHealthtechAgoura Hills, US
Scott Foraker(Executive Officer, Director)Srini Akkaraju(Director)Madhavan Balachandran(Director)Michael Gallo(Director)David Goeddel(Director)C. Alexander Kamb(Director)
Board seatDavid Goeddel· per SEC Form D · $71.5M raise · filed Oct 2020
Berkeley, US
Board seatPeter SvennilsonTim KutzkeyLarry Lasky· per SEC Form D · $46.9M raise · filed Oct 2020
Circle Pharma develops cancer treatments using macrocycle therapies designed to reduce side effects compared to conventional therapies.
BiotechDigital HealthHealthtechMedical DevicesSouth San Francisco, US
Matthew P. Jacobson(Co-founder)David J. Earp(President & CEO)Paul Park(Executive Officer)Scott R. Lokey(Director)Douglas Crawford(Director)Walter Moos(Director)
Board seatJohn JoseyJames EvangelistaPeter SvennilsonPeter Svennilson· per SEC Form D
BiotechCambridge, US
Tom Maniatis(Director)Michael R. Cooper(Executive Officer)Anthony Evnin(Director)James E. Audia(Executive Officer)Keith Dionne(Executive Officer, Director)Matthias Jaffe(Executive Officer)
Board seatPeter SvennilsonDavid Goeddel· per SEC Form D · $100M raise · filed Apr 2018
BiotechSouth San Francisco, US
Jeremy Bender(Executive Officer, Director)Michael Gladstone(Director)Derek DiRocco(Director)Julie Papanek Grant(Director)John Josey(Director)Natalie Holles(Director)
Board seatJohn Josey· per SEC Form D · $130M raise · filed Feb 2021
BiotechWatertown, US
Jesper Gromada(Executive Officer)H. James Magee(Executive Officer)JeenJoo Kang(Director)David Goeddel(Director)Roger Perlmutter(Director)John Ripple(Executive Officer, Director)
Board seatDavid GoeddelJeenJoo Kang· per SEC Form D · $42M raise · filed Nov 2018
BiotechSouth San Francisco, US
Brian Wong(Executive Officer, Director)Beth Seidenberg(Director)Rekha Hemrajani(Executive Officer)William J. Rieflin(Director)Linda Kozick(Director)David Goeddel(Director)
Board seatDavid Goeddel· per SEC Form D · $67.1M raise · filed Jun 2019
Data-driven biotech mining fungal genomic data to discover novel drugs for unmet needs.
BiotechMenlo Park, US
Colin James Bell Harvey(Director)Alex Kolich(Director)Brian T. Naughton(Director)Maureen E. Hillenmeyer(Executive Officer, Director)
Board seatDavid Goeddel· per SEC Form D · $80M raise · filed Oct 2022
BiotechBurlingame, US
Robert Schreiber(Director)John Celebi(Executive Officer)John Diekman(Director)Mark Goldsmith(Director)Carl Gordon(Director)David Goeddel(Director)
Board seatDavid Goeddel· per SEC Form D · $6.3M raise · filed Jan 2015
BiotechNew York, US
William Rieflin(Director)Nancy Thornberry(Executive Officer, Director)Terry McGuire(Director)Kenneth Clark(Executive Officer)Tom Maniatis(Director)Joshua Wolfe(Director)
Board seatTim Kutzkey· per SEC Form D · $44M raise · filed Oct 2016
BiotechSouth San Francisco, US
Cory Nicholas(Executive Officer, Director, Promoter)James Stutz(Executive Officer)Arnold Kriegstein(Director)Stephen Hauser(Director)David Goeddel(Director)
Board seatPeter SvennilsonTim KutzkeyDavid Goeddel· per SEC Form D · $101.7M raise · filed Apr 2025
BiotechSouth San Francisco, US
Diana Peng Bockus(Executive Officer, Director)Tim Kutzkey(Director)Roger M. Perlmutter(Director)Peter Svennilson(Director)
Board seatPeter SvennilsonTim Kutzkey· per SEC Form D · $142M raise · filed Mar 2026
BiotechSouth San Francisco, US
McHenry T. Tichenor, Jr.(Director)William J. Rieflin(Executive Officer, Director)Peter Svennilson(Director)Jin-Long Chen(Executive Officer, Director)Mark Leschly(Director)David V. Goeddel(Director)
Board seatDavid GoeddelPeter Svennilson· per SEC Form D · $60M raise · filed Feb 2015
BiotechLexington, US
Cameron Wheeler(Director)Jonathan Root(Director)Laurence Lasky(Director)Victoria M. Richon(Executive Officer, Director)
Board seatJeff Goater· per SEC Form D · $25M raise · filed Dec 2022
BiotechCambridge, US
Jeff Goater(Director)Peter Fuhrken(Director)Howard Federoff(Executive Officer, Director)Nick Manusos(Executive Officer, Director)David Fallace(Director)Jeff Jonas(Director)
Board seatJeff Goater· per SEC Form D · $81.8M raise · filed Mar 2024
HealthtechSan Francisco, US
Tim Kutzkey(Director)Aadit Shah(Executive Officer)Alexander Marson(Director)
Board seatTim Kutzkey· per SEC Form D · $15M raise · filed Apr 2024
BiotechSouth San Francisco, US
Anna Berkenblit(Director)David Goeddel(Director)Harold Varmus(Director)Craig Parker(Executive Officer, Director)Tim Kutzkey(Director)
Board seatDavid GoeddelTim Kutzkey· per SEC Form D · $50M raise · filed Jun 2020
Tau provides formal verification of compiled binaries by generating mathematical proofs of correctness or identifying bugs, addressing risks from AI-assisted code generation and complex software systems.
AI & Machine LearningCybersecurityDeveloper ToolsEnterprise SoftwareSan Francisco, US
Bristol Myers Squibb is a biopharmaceutical company that develops and delivers medicines across oncology, hematology, neuroscience, immunology, and cardiovascular disease areas.
BiotechHealthtechMedical DevicesNew York, US
InduPro develops proximity-based therapeutics that manipulate spatial relationships of cell surface proteins to enable new disease treatments.
BiotechDeep TechMedical DevicesSeattle, US
Peloton Therapeutics is a clinical-stage pharmaceutical company developing first-in-class small molecule medicines targeting HIF-2α for cancer and other life-threatening conditions, with initial focus on kidney cancer and VHL disease.
BiotechDigital HealthMedical Devices
Plexium is a targeted protein degradation company developing small molecule therapeutics for treating diseases with high unmet medical needs using their proprietary DELTA Discovery platform.
AI & Machine LearningBiotechDeep Tech
Michael Martin, Ph.D.(Chief Executive Officer, President)Jorge F. DiMartinoMichael Martin(President, Chief Executive Officer)
BoardMike Grey(Executive Chairman)in
Merck is a pharmaceutical company focused on developing medicines and vaccines for patients globally, guided by a science-led innovation strategy.
BiotechHealthtechMedical DevicesRahway, US
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Fund performance · per public LP disclosures · 6
as of Nov 2025| Fund | Vintage | Committed | Net IRR | TVPI | DPI |
|---|---|---|---|---|---|
| The Column Group Fund Opportunity Fund IIILPs: Employees' Retirement System of Rhode Island, Carnegie Corporation of New York | 2022 | — | 0.2% | 1.01x | 0.34x |
| The Column Group Fund VLPs: Employees' Retirement System of Rhode Island, Carnegie Corporation of New York | 2022 | — | -19.1% | 0.77x | 0.00x |
| Column Group IVLPs: The Regents of the University of California | 2019 | — | -1.8% | 0.95x | 0.07x |
| Column Group IIILPs: The Regents of the University of California | 2016 | — | 7.7% | 1.25x | 0.78x |
| Column Group IILPs: The Regents of the University of California | 2014 | — | 7.8% | 2.40x | 1.88x |
| The Column Group, L.P.LPs: The Regents of the University of California | 2005 | — | 23.4% | 2.10x | 0.79x |
Source: public limited-partner disclosures (CalPERS, CalSTRS). Net IRR / TVPI / DPI as reported by the limited partner; a fund's early-year IRR is an interim estimate (J-curve).
Frequently asked questions
- What stage does The Column Group invest at?
- The Column Group invests at the Pre-Seed, Seed, Series A, Series B, Growth, Late Stage stages.
- What is The Column Group's typical check size?
- The Column Group typically writes checks of $30M.
- What sectors does The Column Group focus on?
- The Column Group focuses on Biotech, Deep Tech.
- Where is The Column Group located?
- The Column Group is headquartered in San Francisco, US.
- Does The Column Group lead rounds?
- The Column Group typically participates in rounds rather than leading them.
Images
Co-investors · 38
Nextech Invest is a Zurich-based investment firm focused on emerging biotechnology companies, backing transformative cancer medicines and precision medicine advances worldwide.
Atlas Venture is a life sciences venture capital firm with three decades of experience investing in and building biotech and medical innovation companies, including startups launched from its own incubator.
Aisling Capital is an investment firm focused on companies developing and commercializing innovative healthcare products, services, and technologies.
GV (formerly Google Ventures) is a venture investment firm that backs founders across many industries, aiming to build long-term relationships and support companies across multiple stages and milestones.
Lux Capital's portfolio page showcasing select companies across science and technology sectors including AI infrastructure, aerospace, biotech, and productivity software.
8VC is a technology investment firm that builds and invests in ambitious companies across sectors including life sciences, healthcare, manufacturing, enterprise, logistics, and defense.
Foresite Capital is a multi-stage investment firm focused on healthcare and life sciences, backing companies across all stages of growth. It applies a data science-driven approach to invest in businesses leveraging biology and big data to transform healthcare.
.jpeg)
Vida Ventures is a life sciences venture capital firm focused on transforming biomedical innovations into therapies that improve patients' lives.
Cure Ventures is a venture firm focused on backing entrepreneurs building life-changing therapeutics, partnering closely with founders from company formation onward.
New Enterprise Associates (NEA) is a venture capital firm that invests in and provides long-term support to founders building new companies.
Canaan is an early-stage venture capital firm backing founders with transformative ideas across technology and healthcare.
OrbiMed is a global healthcare-focused investment firm providing financing and operational support to companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.
▶26 more co-investors
5AM VenturesSanofi VenturesKleiner PerkinsDCVC (Data Collective)Innovation EndeavorsARCH Venture PartnersRA CapitalOUP (Osage University Partners)Dimension CapitalThird Rock VenturesSamsara BioCapitalGeneral CatalystFounders FundUS Venture PartnersTwo Sigma VenturesGeneral AtlanticM12 (Microsoft's Venture Fund)Versant VenturesSR One Capital ManagementPivotal bioVenture PartnersPfizer Venture InvestmentsMPM CapitalOmega FundsLightstone VenturesLeaps by BayerAstellas Venture Management LLC
Firms observed investing alongside The Column Group, from public investor directories. Shared companies are the overlap with The Column Group's recorded portfolio.
Similar investors
8VC is a technology investment firm that builds and invests in ambitious companies across sectors including life sciences, healthcare, manufacturing, enterprise, logistics, and defense.
Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests from seed to growth stages across artificial intelligence, health, and sustainability-focused technologies.
Inveready is a Spanish alternative investment firm founded in 2008, offering investment solutions and wealth management services across the small and mid-market segment in Spain.
Octopus Ventures is a founder-focused European venture capital firm that backs mission-driven startups across seven core sectors, investing from idea stage through growth with a focus on pre-seed to Series A.
Osage University Partners invests in startups commercializing university and research-driven breakthroughs across technology and life sciences.